Oravecz T, Pall M, Roderiquez G, Gorrell M D, Ditto M, Nguyen N Y, Boykins R, Unsworth E, Norcross M A
Division of Hematologic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA.
J Exp Med. 1997 Dec 1;186(11):1865-72. doi: 10.1084/jem.186.11.1865.
CD26 is a leukocyte activation marker that possesses dipeptidyl peptidase IV activity but whose natural substrates and immunological functions have not been clearly defined. Several chemo-kines, including RANTES (regulated on activation, normal T cell expressed and secreted), have now been shown to be substrates for recombinant soluble human CD26. The truncated RANTES(3-68) lacked the ability of native RANTES(1-68) to increase the cytosolic calcium concentration in human monocytes, but still induced this response in macrophages activated with macrophage colony-stimulating factor. Analysis of chemokine receptor messenger RNAs and patterns of desensitization of chemokine responses showed that the differential activity of the truncated molecule results from an altered receptor specificity. RANTES(3-68) showed a reduced activity, relative to that of RANTES(1-68), with cells expressing the recombinant CCR1 chemokine receptor, but retained the ability to stimulate CCR5 receptors and to inhibit the cytopathic effects of HIV-1. Our results indicate that CD26-mediated processing together with cell activation-induced changes in receptor expression provides an integrated mechanism for differential cell recruitment and for the regulation of target cell specificity of RANTES, and possibly other chemokines.
CD26是一种白细胞活化标志物,具有二肽基肽酶IV活性,但其天然底物和免疫功能尚未明确界定。现在已经证明,包括RANTES(活化调节、正常T细胞表达和分泌)在内的几种趋化因子是重组可溶性人CD26的底物。截短的RANTES(3 - 68)缺乏天然RANTES(1 - 68)在人单核细胞中增加胞质钙浓度的能力,但仍能在巨噬细胞集落刺激因子激活的巨噬细胞中诱导这种反应。对趋化因子受体信使核糖核酸和趋化因子反应脱敏模式的分析表明,截短分子的差异活性源于受体特异性的改变。相对于RANTES(1 - 68),RANTES(3 - 68)对表达重组CCR1趋化因子受体的细胞活性降低,但保留了刺激CCR5受体和抑制HIV - 1细胞病变效应的能力。我们的结果表明,CD26介导的加工以及细胞活化诱导的受体表达变化为趋化因子RANTES以及可能的其他趋化因子的差异细胞募集和靶细胞特异性调节提供了一种综合机制。